US regulatory status: approved.
pharma · Osteoarthritis · Osteoporosis
Nordic Bioscience
Nordic Bioscience A/S
Nordic Bioscience drug portfolio — 10 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Herlev, DK HQ
1991 Founded
228 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Herlev, DK
- Founded
- 1991
- Employees
- 228
- Programs
- 5
- Drugs
- 10
- Patents
- 0
Nordic Bioscience pipeline
Portfolio lens on 10 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Nordic Bioscience drug portfolio — 10 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Nordic Bioscience in public FDA and regional records. Molecular target: Calcitonin receptor.
- Target
- Calcitonin receptor
- Mechanism
- Calcitonin receptor agonist
-
Development asset linked to Nordic Bioscience in public FDA and regional records.
-
durvalumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.
- Target
- Programmed cell death 1 ligand 1
- Mechanism
- Programmed cell death 1 ligand 1 inhibitor
-
Development asset linked to Nordic Bioscience in public FDA and regional records.
-
olaparib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: PARP 1, 2 and 3.
- Target
- PARP 1, 2 and 3
- Mechanism
- PARP 1, 2 and 3 inhibitor
-
sargramostim
Antineoplastic and immunomodulating agents (L03)US regulatory status: approved. Molecular target: Granulocyte-macrophage colony-stimulating factor receptor.
- Target
- Granulocyte-macrophage colony-stimulating factor receptor
- Mechanism
- Granulocyte-macrophage colony-stimulating factor receptor agonist
-
Development asset linked to Nordic Bioscience in public FDA and regional records.
-
Development asset linked to Nordic Bioscience in public FDA and regional records.
-
Development asset linked to Nordic Bioscience in public FDA and regional records.